Biosergen (BIOSGN) Stock Overview
A biotech company, develops antifungal products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BIOSGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Biosergen AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 43.60 |
| 52 Week High | SEK 67.80 |
| 52 Week Low | SEK 28.10 |
| Beta | 0.32 |
| 1 Month Change | 9.00% |
| 3 Month Change | -12.80% |
| 1 Year Change | 8.19% |
| 3 Year Change | -65.67% |
| 5 Year Change | n/a |
| Change since IPO | -93.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOSGN | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -4.0% | 2.6% | -1.0% |
| 1Y | 8.2% | 7.2% | 2.5% |
Return vs Industry: BIOSGN exceeded the Swedish Biotechs industry which returned 7.2% over the past year.
Return vs Market: BIOSGN exceeded the Swedish Market which returned 2.5% over the past year.
Price Volatility
| BIOSGN volatility | |
|---|---|
| BIOSGN Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: BIOSGN has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BIOSGN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 1 | Tine Olesen | www.biosergen.net |
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Biosergen AB (publ) Fundamentals Summary
| BIOSGN fundamental statistics | |
|---|---|
| Market cap | SEK 102.38m |
| Earnings (TTM) | -SEK 40.82m |
| Revenue (TTM) | n/a |
Is BIOSGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOSGN income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 40.82m |
| Earnings | -SEK 40.82m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | -17.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BIOSGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/15 15:22 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biosergen AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Herman Kuntscher | Carlsquare AB |